



Survival Benefits of Palbociclib Plus Endocrine Therapy in HR+/HER2- Advanced Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Trials

Nasrin Mansouri¹, Seyed Ghasem Mirbahari^{2,3,*}, Roya Zandian⁴, Negin Farshchian⁴

¹Department of Obstetrics and Gynecology, Clinical Research Development Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

²Jam Pathobiology Laboratory, Kermanshah, Iran

³Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran

⁴Department of Radiation Oncology, Faculty of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran

***Corresponding Author:** Molecular Pathology Research Center, Imam Reza Hospital, Kermanshah University of Medical Sciences, Kermanshah, Iran. Email: sgmirbahari@gmail.com

Received: 16 November, 2025; Accepted: 22 November, 2025

Abstract

Context: Endocrine therapy remains the standard of care for hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (BC), but its efficacy is limited in patients with prior endocrine exposure. Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i), such as palbociclib, have emerged as a promising strategy to enhance treatment outcomes.

Objectives: This systematic review and meta-analysis aimed to evaluate the efficacy of palbociclib combined with endocrine therapy (ET) versus endocrine therapy alone in improving survival outcomes.

Methods: A systematic literature search was conducted in PubMed, Scopus, and Web of Science up to November 9, 2025, following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Randomized controlled trials (RCTs) comparing palbociclib plus ET with ET alone or placebo plus ET in HR+/HER2- advanced or metastatic BC patients were included. Outcomes assessed were progression-free survival (PFS) and overall survival (OS). Hazard ratios (HRs) and 95% confidence intervals (CIs) were pooled.

Results: Seven RCTs, including 1,758 patients, met inclusion criteria. Pooled analysis demonstrated that palbociclib combined with ET significantly improved PFS compared with ET alone (HR = 0.492; $P < 0.001$). A trend toward improved OS was observed (HR = 0.883; $P = 0.075$), though this did not reach statistical significance. Subgroup analyses and bias assessments confirmed consistent efficacy across populations and low risk of methodological bias, with no evidence of publication bias.

Conclusions: Palbociclib combined with ET provides substantial improvements in PFS and demonstrates a favorable trend in OS for patients with HR+/HER2- advanced BC.

Keywords: Breast Cancer, Palbociclib, CDK4/6i, Endocrine Therapy, Progression-Free Survival

1. Introduction

For decades, breast cancer (BC) has been the most prevalent cancer worldwide, with approximately 2.26 million new cases diagnosed annually (1). Recently, cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have become a focal point in BC research (2). Researchers have developed a series of CDK4/6i, including

palbociclib, ribociclib, and abemaciclib (3). Among BC subtypes, hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) tumors are the most prevalent, accounting for approximately 70% of all cases (4).

Cyclin-dependent kinase 4/6 inhibitors, namely palbociclib, ribociclib, and abemaciclib, when

combined with endocrine therapy (ET), have been shown to double median progression-free survival (PFS) compared with single-agent ET in both first-line and later-line settings in pivotal phase 3 trials. Additionally, they improved median overall survival (OS) in some cases (5, 6). When combined with fulvestrant, these three drugs also significantly improved PFS in patients whose tumors progressed during prior ET (7-9).

Palbociclib is a first-in-class, potent, highly selective, orally administered, reversible cyclin-dependent kinase 4/6 inhibitor (10). Preclinical studies revealed that palbociclib combined with ET preferentially and synergistically inhibits the cell cycle in human estrogen receptor-positive BC cell lines (11). However, outcomes may vary depending on population, as some studies included patients of Asian ethnicity, whose dietary habits and medical environments differ from Western countries, potentially influencing clinical outcomes (12, 13). Here, we report PFS and OS data evaluating the efficacy of palbociclib combined with ET compared with placebo plus ET or ET alone in patients with advanced BC.

2. Materials and Methods

2.1. Study Design and Protocol

This systematic review and meta-analysis was conducted according to the Preferred Reporting Items for PRISMA guidelines (14). The study protocol was designed based on the Population, Intervention, Comparison, and Outcomes (PICO) framework. PICO question: In patients with HR+ and HER2- or metastatic BC (Population), does the combination of palbociclib plus ET (Intervention), compared with ET alone or placebo plus ET (Comparison), improve survival outcomes such as PFS and OS (Outcome)?

2.2. Search Strategy

A comprehensive literature search was conducted in PubMed, Scopus, and Web of Science databases from inception to November 9, 2025, without any language or date restrictions. The following search terms were used: ("breast cancer" or "breast neoplasm*" or "breast carcinoma" or "mammary carcinoma") and ("palbociclib" or "Ibrance" or "CDK4/6 inhibitor" or "cyclin-dependent kinase 4/6 inhibitor") and ("randomized controlled trial" or "randomised

controlled trial" or "randomized trial" or "randomised trial" or "randomized study" or "randomised study"). Additionally, a manual search was performed in Google Scholar (first ten pages of results) and the reference lists of relevant reviews and original studies to identify any additional eligible trials.

2.3. Eligibility Criteria

Studies were included if they met the following criteria: (A) Randomized controlled trial (RCT). (B) Adult patients with HR+/HER2- advanced or metastatic BC. (C) Intervention group was palbociclib combined with ET (e.g., letrozole or fulvestrant). (D) Control group was ET alone or placebo plus ET. (E) Studies reported at least one survival endpoint – PFS or OS.

2.4. Data Extraction and Quality Assessment

Two investigators independently extracted data on study characteristics, patient demographics, interventions, and outcomes. Discrepancies were resolved by discussion or consultation with a third reviewer. The Cochrane Collaboration's Risk of Bias Tool was used to evaluate seven domains.


2.5. Statistical Analysis

Hazard ratios (HRs) and 95% confidence intervals (CIs) for PFS and OS were extracted from each trial. A fixed-effect model (Mantel-Haenszel method) was applied to calculate pooled estimates, accounting for potential between-study heterogeneity. Heterogeneity was assessed using the I^2 statistic, with $I^2 > 50\%$ indicating substantial heterogeneity. Publication bias was evaluated visually by funnel plots and statistically using Egger's and Begg's tests, with a $P < 0.10$ indicating significant bias. All analyses were performed using Comprehensive Meta-Analysis (version 3.0) software.

3. Results

3.1. Study Selection

A total of 248 records were identified through database searches, including 26 from PubMed, 63 from Web of Science, and 159 from Scopus, with no additional records obtained from other sources. After removing duplicates, 192 records remained for screening. Of these, 173 were excluded based on title and abstract review,

**Figure 1.** Flowchart of the study selection**Table 1.** Characteristics of Studies Included in the Meta-Analysis

The First Study, Publication Year	Registry Number	Intervention Group (N)	Control Group (N)	Outcome	Follow-up Time (Months)
Finn, 2020 (15)	NCT00721409	Palbociclib + Letrozole (84)	Letrozole (81)	OS	84
Cristofanilli, 2022 (16)	NCT01942135	Palbociclib + Fulvestrant (347)	Placebo + Fulvestrant (174)	OS	84
Slamon, 2024 (17)	NCT01740427	Palbociclib + Letrozole (444)	Placebo + Letrozole (222)	OS	108
Mukai, 2019 (18)	NCT01740427	Palbociclib + Letrozole (32)	Placebo + Letrozole (14)	PFS	33
Albanell, 2022 (19)	NCT02690480	Palbociclib + Fulvestrant (265)	Placebo + Fulvestrant (130)	PFS	36
Cristofanilli, 2016 (7)	NCT01942135	Palbociclib + Fulvestrant (265)	Placebo + Fulvestrant (130)	PFS	15
Turner, 2015 (20)	NCT01942135	Palbociclib + Fulvestrant (347)	Placebo + Fulvestrant (174)	PFS	12

Abbreviations: OS, overall survival; PFS, progression-free; N, number of cases.

leaving 19 full-text articles assessed for eligibility. Twelve of these were excluded for specific reasons, including three single-arm trials, two review articles, one study involving an intervention group with capecitabine, and six duplicate records. Ultimately, seven articles (7, 15-20) met the inclusion criteria and were incorporated into

both the systematic review and the meta-analysis (Figure 1).

3.2. Characteristics of Cases

The seven studies included in the meta-analysis evaluated the efficacy of palbociclib combined with ET (letrozole or fulvestrant) in patients with BC (Table 1).




Figure 2. Forest plot of hazard ratio (HR) of A, overall survival (OS) in the intervention group versus the control group; B, progression-free survival (PFS) in the intervention group versus the control group^(7,15-20)

These trials, conducted between 2015 and 2024, were large-scale, randomized controlled trials registered in recognized clinical trial databases.

Among them, three studies reported OS outcomes, while four studies focused on PFS. The sample sizes across intervention groups ranged from 32 to 444 patients, with control groups including 14 to 222 patients. The follow-up duration varied substantially, from 12 months to 108 months, indicating a mix of short- and long-term data across studies.

3.3. Pooled Analyses

Figure 2A presents a forest plot summarizing the HRs for OS comparing the intervention group (palbociclib plus ET) with the control group (ET alone or with placebo) across three studies. The pooled analysis yielded a pooled HR of 0.883 (95% CI: 0.770 - 1.013, $P = 0.075$), indicating a trend toward improved survival in the intervention group, though this result did not reach statistical significance. Overall, these findings suggest

that palbociclib in combination with ET may modestly enhance OS in patients with hormone receptor-positive BC, but further evidence is required to confirm a definitive survival benefit.

Figure 2B illustrates a forest plot showing the HRs for PFS comparing the intervention group (palbociclib plus ET) with the control group (ET alone or with placebo) across four studies. The pooled analysis demonstrated a combined HR of 0.492 (95% CI: 0.430 - 0.563, $P < 0.001$), indicating a significant 48% reduction in the risk of disease progression or death with palbociclib-based treatment. All studies consistently favored the intervention group, with CIs that did not cross the line of no effect. These findings strongly support that palbociclib in combination with ET provides a substantial and statistically significant improvement in PFS compared with ET alone in patients with hormone receptor-positive BC.

Figure 3A presents a funnel plot evaluating potential publication bias for the OS analysis comparing the intervention group (palbociclib plus ET) with the




Figure 3. Funnel plot of HR of A, overall survival (OS) in the intervention group versus the control group; B, progression-free survival in the intervention group versus the control group.

control group. The plot shows a symmetric distribution of studies around the pooled effect size, suggesting the absence of substantial publication bias. Statistical assessment using Begg's test ($P = 0.601$) and Egger's test ($P = 0.968$) further confirmed this finding, as both P -values were greater than 0.10. Therefore, there was no evidence of significant publication bias among the included studies assessing OS.

Figure 3B shows a funnel plot of the HR for PFS comparing the intervention group with the control group. Begg's test yielded a P -value of 0.796, and Egger's test yielded a P -value of 0.576. Since both P -values are greater than 0.10, there is no evidence of significant publication bias.

Figure 4 presents a comprehensive assessment of bias risk across the included clinical studies. Section A, the risk of bias summary, shows that 100% of the studies evaluated exhibit a low risk of bias across all seven domains. This is visually represented by fully green bars, indicating methodological consistency and rigor.

Section B, the risk of bias graph, reinforces these findings by displaying a matrix in which each study shows a low risk of bias in every domain, marked by green circles with plus signs. Together, these visuals confirm that the studies included in the analysis are of high quality and free from significant methodological flaws, enhancing the reliability and validity of the overall evidence base.

4. Discussion

Seven randomized controlled trials were selected from an initial pool of 248 records to evaluate the efficacy of palbociclib combined with ET in hormone receptor-positive BC. These studies, conducted between 2015 and 2024, varied in sample size and follow-up duration, and reported either OS or PFS outcomes. Pooled analysis showed a non-significant trend toward improved OS, but a significant benefit in PFS, indicating a 48% reduction in disease progression or death. No substantial publication bias was detected, and all




Figure 4. Bias risk assessment. A, risk of bias summary; B, risk of bias graph. (7,15-20)

studies demonstrated a uniformly low risk of bias across key methodological domains, confirming the reliability of the evidence.

The results reinforce the key observation that endocrine monotherapy shows limited efficacy in patients whose disease has progressed despite prior endocrine sensitivity, highlighting the need for routine use of more effective combination therapies (7, 20-22). The combination of hormone therapy and palbociclib has been shown to significantly enhance treatment outcomes in patients, leading to higher objective response rates, increased clinical benefit, and prolonged PFS compared with hormone therapy alone (7, 18, 19). Subgroup analyses of patients from various Asian countries, including Korea and Japan, further support the efficacy of palbociclib in Asian patients with estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced BC, demonstrating consistent improvements in PFS and clinical response across these populations (18, 23, 24).

Recent evidence from two systematic reviews and meta-analyses strongly supports the superiority of combining CDK4/6i with ET over ET alone, demonstrating enhanced efficacy in terms of objective

response, clinical benefit, and PFS for the vast majority of patients (4, 25). This synergy underscores the value of cyclin-dependent kinase 4/6 inhibition in overcoming resistance and improving disease control in endocrine-sensitive BC.

Limitations: (1) Limited number of trials and OS data – Only seven randomized controlled trials were included, and just three reported OS outcomes, which reduces statistical power and limits conclusions about long-term survival benefits. (2) Variability in study design and follow-up – The included trials differed in sample sizes, interventions (letrozole versus fulvestrant), and follow-up durations (12-108 months) that may affect pooled estimates. (3) Restricted subgroup and real-world analysis – The meta-analysis did not explore patient subgroups (e.g., age, prior treatments, menopausal status) or real-world outcomes, limiting the ability to identify which populations benefit most from palbociclib.

5. Conclusions

This systematic review and meta-analysis of seven randomized controlled trials demonstrated that

palbociclib in combination with ET provides a significant improvement in PFS (HR = 0.492, P < 0.001) in patients with hormone receptor-positive BC, while showing a non-significant trend toward improved OS (HR = 0.883, P = 0.075). The included studies were of high methodological quality, with uniformly low risk of bias and no evidence of publication bias, supporting the robustness of the findings.

The results highlight the clinical value of palbociclib as an effective addition to ET, particularly in delaying disease progression. This benefit translates into meaningful improvements in patient management, offering extended disease control and potentially better quality of life. Although the OS advantage did not reach statistical significance, the consistent PFS benefit underscores palbociclib's role as a standard therapeutic option in hormone receptor-positive BC.

Further long-term studies and pooled analyses with larger patient populations are needed to clarify the impact of palbociclib on OS and to identify subgroups that may derive the greatest benefit. Future research should also explore biomarkers predictive of response, cost-effectiveness analyses, and real-world outcomes to optimize patient selection and treatment strategies.

Footnotes

AI Use Disclosure: The authors declare that no generative AI tools were used in the creation of this article.

Authors' Contribution: Study concept and design, Nasrin Mansouri; Acquisition of data, Nasrin Mansouri; Analysis and interpretation of data, Seyed Ghasem Mirbahari; Drafting of the manuscript, Seyed Ghasem Mirbahari; Critical revision of the manuscript for important intellectual content, Nasrin Mansouri, Seyed Ghasem Mirbahari, Roya Zandian and Negin Farshchian; Statistical analysis, Nasrin Mansouri and Seyed Ghasem Mirbahari; Administrative, technical, and material support, Roya Zandian and Negin Farshchian; Study supervision, Nasrin Mansouri.

Conflict of Interests Statement: The authors declare no conflict of interest.

Data Availability: The dataset presented in the study is available on request from the corresponding author

during submission or after publication.

Funding/Support: The present study received no funding/support.

References

1. Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. *CA Cancer J Clin.* 2024;74(1):12-49. [PubMed ID: 38230766]. <https://doi.org/10.3322/caac.21820>.
2. Wekking D, Leoni VP, Lamberti M, Dessi M, Pretta A, Cadoni A, et al. CDK4/6 inhibition in hormone receptor-positive/HER2-negative breast cancer: Biological and clinical aspects. *Cytokine Growth Factor Rev.* 2024;75:57-64. [PubMed ID: 37838584]. <https://doi.org/10.1016/j.cytoogr.2023.10.001>.
3. Bottcher TM, Cold S, Jensen AB. Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib. *Acta Oncol.* 2019;58(2):147-53. [PubMed ID: 30375908]. <https://doi.org/10.1080/0284186X.2018.1532603>.
4. Schettini F, Giuliano M, Giudici F, Conte B, De Placido P, Venturini S, et al. Endocrine-Based Treatments in Clinically-Relevant Subgroups of Hormone Receptor-Positive/HER2-Negative Metastatic Breast Cancer: Systematic Review and Meta-Analysis. *Cancers.* 2021;13(6). [PubMed ID: 33810205]. [PubMed Central ID: PMC8004645]. <https://doi.org/10.3390/cancers13061458>.
5. Giuliano M, Schettini F, Rognoni C, Milani M, Jerusalem G, Bachet T, et al. Endocrine treatment versus chemotherapy in postmenopausal women with hormone receptor-positive, HER2-negative, metastatic breast cancer: a systematic review and network meta-analysis. *Lancet Oncol.* 2019;20(10):1360-9. [PubMed ID: 31494037]. [https://doi.org/10.1016/S1470-2045\(19\)30420-6](https://doi.org/10.1016/S1470-2045(19)30420-6).
6. Schettini F, Giudici F, Giuliano M, Cristofanilli M, Arpino G, Del Mastro L, et al. Overall Survival of CDK4/6-Inhibitor-Based Treatments in Clinically Relevant Subgroups of Metastatic Breast Cancer: Systematic Review and Meta-Analysis. *J Natl Cancer Inst.* 2020;112(11):1089-97. [PubMed ID: 32407488]. [PubMed Central ID: PMC7669227]. <https://doi.org/10.1093/jnci/djaa071>.
7. Cristofanilli M, Turner NC, Bondarenko I, Ro J, Im SA, Masuda N, et al. Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol.* 2016;17(4):425-39. [PubMed ID: 26947331]. [https://doi.org/10.1016/S1470-2045\(15\)00613-0](https://doi.org/10.1016/S1470-2045(15)00613-0).
8. Sledge GJ, Toi M, Neven P, Sohn J, Inoue K, Pivot X, et al. MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy. *J Clin Oncol.* 2017;35(25):2875-84. [PubMed ID: 28580882]. <https://doi.org/10.1200/JCO.2017.73.7585>.
9. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Phase III Randomized Study of Ribociclib and Fulvestrant in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: MONALEESA-3. *J Clin Oncol.* 2018;36(24):2465-72. [PubMed ID: 29860922]. <https://doi.org/10.1200/JCO.2018.78.9909>.

10. Fry DW, Harvey PJ, Keller PR, Elliott WL, Meade M, Trachet E, et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. *Mol Cancer Ther.* 2004;3(11):1427-38. [PubMed ID: 15542782].
11. Finn RS, Dering J, Conklin D, Kalous O, Cohen DJ, Desai AJ, et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro. *Breast Cancer Res.* 2009;11(5):R77. [PubMed ID: 19874578]. [PubMed Central ID: PMC2790859]. <https://doi.org/10.1186/bcr2419>.
12. Cook G, Kim H. From Regulatory Approval to Subsidized Patient Access in the Asia-Pacific Region: A Comparison of Systems Across Australia, China, Japan, Korea, New Zealand, Taiwan, and Thailand. *Value Health Reg Issues.* 2015;6:40-5. [PubMed ID: 29698191]. <https://doi.org/10.1016/j.vhri.2015.03.013>.
13. Song S, Song WO. National nutrition surveys in Asian countries: surveillance and monitoring efforts to improve global health. *Asia Pac J Clin Nutr.* 2014;23(4):514-23. [PubMed ID: 25516308]. <https://doi.org/10.6133/apjcn.2014.23.4.09>.
14. Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. *BMJ.* 2021;372:n160. [PubMed ID: 33781993]. [PubMed Central ID: PMC8005925]. <https://doi.org/10.1136/bmj.n160>.
15. Finn RS, Boer K, Bondarenko I, Patel R, Pinter T, Schmidt M, et al. Overall survival results from the randomized phase 2 study of palbociclib in combination with letrozole versus letrozole alone for first-line treatment of ER+/HER2- advanced breast cancer (PALOMA-1, TRIO-18). *Breast Cancer Res Treat.* 2020;183(2):419-28. [PubMed ID: 32683565]. [PubMed Central ID: PMC7383036]. <https://doi.org/10.1007/s10549-020-05755-7>.
16. Cristofanilli M, Rugo HS, Im SA, Slamon DJ, Harbeck N, Bondarenko I, et al. Overall Survival with Palbociclib and Fulvestrant in Women with HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-blind, Phase III Randomized Study. *Clin Cancer Res.* 2022;28(16):3433-42. [PubMed ID: 35552673]. [PubMed Central ID: PMC9662922]. <https://doi.org/10.1158/1078-0432.CCR-22-0305>.
17. Slamon DJ, Dieras V, Rugo HS, Harbeck N, Im SA, Gelmon KA, et al. Overall Survival With Palbociclib Plus Letrozole in Advanced Breast Cancer. *J Clin Oncol.* 2024;42(9):994-1000. [PubMed ID: 38252901]. [PubMed Central ID: PMC10950136]. <https://doi.org/10.1200/JCO.23.00137>.
18. Mukai H, Shimizu C, Masuda N, Ohtani S, Ohno S, Takahashi M, et al. Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. *Int J Clin Oncol.* 2019;24(3):274-87. [PubMed ID: 30515674]. [PubMed Central ID: PMC6399183]. <https://doi.org/10.1007/s10147-018-1353-9>.
19. Albanell J, Martinez MT, Ramos M, O'Connor M, de la Cruz-Merino I, Santabarla A, et al. Randomized phase II study of fulvestrant plus palbociclib or placebo in endocrine-sensitive, hormone receptor-positive/HER2-advanced breast cancer: GEICAM/2014-12 (FLIPPER). *Eur J Cancer.* 2022;161:26-37. [PubMed ID: 34902765]. <https://doi.org/10.1016/j.ejca.2021.11.010>.
20. Turner NC, Ro J, Andre F, Loi S, Verma S, Iwata H, et al. Palbociclib in Hormone-Receptor-Positive Advanced Breast Cancer. *N Engl J Med.* 2015;373(3):209-19. [PubMed ID: 26030518]. <https://doi.org/10.1056/NEJMoa1505270>.
21. Baselga J, Campone M, Piccart M, Burris H3, Rugo HS, Sahmoud T, et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. *N Engl J Med.* 2012;366(6):520-9. [PubMed ID: 22149876]. [PubMed Central ID: PMC5705195]. <https://doi.org/10.1056/NEJMoa1109653>.
22. Kaufman B, Mackey JR, Clemens MR, Bapsy PP, Vaid A, Wardley A, et al. Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TANDEM study. *J Clin Oncol.* 2009;27(33):5529-37. [PubMed ID: 19786670]. <https://doi.org/10.1200/JCO.2008.20.6847>.
23. Masuda N, Inoue K, Nakamura R, Rai Y, Mukai H, Ohno S, et al. Palbociclib in combination with fulvestrant in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-3 subgroup analysis of Japanese patients. *Int J Clin Oncol.* 2019;24(3):262-73. [PubMed ID: 30392115]. [PubMed Central ID: PMC6399170]. <https://doi.org/10.1007/s10147-018-1359-3>.
24. Kim JH, Im SA, Sim SH, Bananis E, Huang X, Kim HS, et al. Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. *J Breast Cancer.* 2021;24(1):97-105. [PubMed ID: 33634624]. [PubMed Central ID: PMC7920865]. <https://doi.org/10.4048/jbc.2021.24.e13>.
25. Porte B, Carton M, Lerebours F, Brain E, Loirat D, Haroun L, et al. Real life efficacy of palbociclib and endocrine therapy in HR positive, HER2 negative advanced breast cancer. *Breast.* 2020;54:303-10. [PubMed ID: 33242757]. [PubMed Central ID: PMC7695984]. <https://doi.org/10.1016/j.breast.2020.11.008>.